NTB-A/SLAMF6/CD352 Antibody [Alexa Fluor® 350]

• Reactivity: Mu
• Applications: WB, Flow, CyTOF-ready
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor 350

NTB-A/SLAMF6/CD352 Antibody [Alexa Fluor® 350] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse NTB‑A/SLAMF6
  Glu31-Asn239
  Accession # Q9ET39
• Specificity: Detects mouse NTB‑A/SLAMF6 in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for NTB-A/SLAMF6/CD352 Antibody [Alexa Fluor® 350]

• Activating NK receptor
• CD352 antigen
• CD352
• KALIFLJ50657
• Ly108
• NK-T-B-antigen
• NTBA receptor
• NTBA
• NTB-A
• NTB-AMGC104953
• NTBAT- and B-cell antigen
• SF2000
• SLAM family member 6
• SLAMF6

Background

NTB-A, also known as Ly108 and SLAMF6, is a 60 kDa type I transmembrane glycoprotein that belongs to the SLAM subgroup of the CD2 family (1). Mature mouse NTB-A consists of a 209 amino acid (aa) ECD with one Ig-like V-type and one Ig-like C2-type domain, a 23 aa transmembrane segment, and an 89 aa cytoplasmic domain with two immunoreceptor tyrosine-based switch motifs ITSMs (2). Within the ECD, mouse NTB-A shares 48% and 70% aa sequence identity with human and rat NTB-A, respectively. The ECD of mouse NTB-A shares 20%‑34% aa sequence identity with comparable regions of mouse 2B4, BLAME, CD2F-10, CD84, CD229, CRACC, and SLAM. An alternatively spliced isoform diverges after the second ITSM (2). NTB-A is expressed on the surface of NK, T, and B lymphocytes as well as eosinophils (3‑5). It interacts homophilically through weak associations between the Ig-V type domains (5‑7). NTB-A functions as an activating coreceptor on NK and T cells (3, 5, 6, 8). Tyrosine phosphorylation in the membrane proximal ITSM enables specific association with EAT-2, an interaction that is required for NTB-A mediated cytotoxicity of NK cells (9). Phosphorylation-dependent NTB-A association with SAP is required for full production of NK cell IFN-gamma (5, 9). This interaction is independent of EAT-2 binding and appears to involve the membrane distal ITSM (5, 9). NTB-A deficient mice show weakened Th2 responses and elevated levels of neutrophil-derived inflammatory mediators (10). On B cells, NTB-A modulates immunoglobulin class switching and the balance between tolerance and autoimmunity (5, 11). The isoform with the divergent C-terminal tail is overexpressed in B cells from lupus-prone mice (11).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q9ET39()